close

  • home Home

  • linked_services Solutions keyboard_arrow_down

    • biotech Core Disciplines keyboard_arrow_down

      • View All
      • Quality Control
      • EQA
      • Chemistry
      • Immunoassay
      • Molecular
      • Point of Care
      • Toxicology
      • Food Diagnostics
      • BioSciences
      • BioReagents
      • Veterinary

    • neurology Disease Areas keyboard_arrow_down

      • View All
      • Acute Kidney Injury
      • Alzheimer's Disease
      • Chronic Kidney Disease
      • Chronic Lung Infection
      • Colorectal Cancer
      • Familial Hypercholesterolemia
      • Gastrointestinal
      • Hyperinflammation
      • Immunodeficiency
      • Neurovascular Dysfunction
      • Pancreatic Cancer
      • Urinary Tract Infection
      • Female Bladder Cancer Array
      • Acute Respiratory Distress Syndrome (ARDS)

    • store Online Store

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

    • Our Story
    • Our Vision
    • Our Team
    • Partners & Sponsorships
    • Charity Partners
    • Collaborators
    • Careers

  • mail Contact

  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu
Randox Health search

Get in touch to discover more

To find out more about the Acute Kidney Injury , enquire now.

Make an Enquiry mail

Key Benefits

Multiplex detection of multiple kidney damage biomarkers from a single patient sample.

Novel combination of biomarkers increases sensitivity and accuracy compared to creatinine

Earlier identification of CKD allows for earlier intervention and better patient outcomes

Applications in safety endpoint monitoring or drug-related renal toxicity during clinical trials

Identify the risk of CKD development/progression following an AKI episode

Utilises biomarkers to profile slow vs rapid CKD progression

CKD refers to abnormal kidney function and/or structure, present for a minimum of 3 months.

Existing diagnostic tests like creatinine cannot reliably detect early-stage CKD at which intervention could be more effective.

Utilising patented biochip technology, the CKD array could improve patient risk stratification and monitor the effectiveness of treatment.   Earlier detection of CKD allows for earlier intervention and treatment to prevent further kidney damage.  The diagram below illustrates the earlier detection possible with biochip technology.

1. Normal-High (no symptoms)
arrow_right
Randox Biochip diagnoses CKD
arrow_right
2. Mild disease
arrow_right
3. Mild-moderate
arrow_right
4. Moderate-severe disease
arrow_right
Earliest diagnosis of current technology
arrow_right
5. Severe disease
arrow_right
6. Systematic failure

CKD Array I

EGF

Regulates renal cell proliferation, fibrosis, and inflammation. Produced in response to injury.

IL-8

Involved in recruiting neutrophils to sites of injury and stimulating their response.

sTNFR1

Used to identify an increase in inflammatory conditions like CKD.

sTNFR2

Used to identify an increase in inflammatory conditions like CKD.

FABP1

Contributes to reducing oxidative stress in the kidneys.

D-Dimer

A fibrin degradation product, and an index of coagulation and fibrinolysis.

MIP-1 alpha

Plays role in inflammatory response at sites of injury or infection.

CKD Array II

CRP

An acute phase reactant involved in inflammation.

Cystatin C

Marker of kidney filtration dysfunction and injury.

C3a des Arg

Produces a local inflammatory response.

NGAL

State of the art biomarker for CKD.

The Evidence Investigator

The CKD Array I and CKD Array II are available for research use only on the Evidence Investigator, a semi-automated benchtop immunoassay analyser.